文献速递前列腺癌

转移性去势抵抗性前列腺癌患者接受醋酸阿比特龙联合泼尼松治疗后雄激素信号导向治疗的临床结局:COU-AA-302的事后分析

Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
PubMed 文献 · Eur Urol · 2017-03-15

COU-AA-302事后分析评估经醋酸阿比特龙联合泼尼松治疗后进展的转移性去势抵抗性前列腺癌患者,后续接受醋酸阿比特龙联合泼尼松(55例)或恩扎卢胺(33例)的临床结局。前列腺特异性抗原(PSA)应答率分别为44%和67%,中位至PSA进展时间分别为3.9个月和2.8个月;多数患者(68%)在后续治疗前接受了中间化疗。作者认为后续治疗的临床获益有限。

要点

  • 后续醋酸阿比特龙联合泼尼松组PSA应答率44%,恩扎卢胺组67%。
  • 后续醋酸阿比特龙联合泼尼松组中位至PSA进展3.9个月,恩扎卢胺组2.8个月。
  • 68%患者在后续治疗前接受了中间化疗,后续治疗临床获益有限。

核心结论

  • 作者认为,对于经醋酸阿比特龙联合泼尼松治疗后进展的患者,后续使用醋酸阿比特龙联合泼尼松或恩扎卢胺的临床获益有限。

研究设计与样本

  • COU-AA-302试验的事后分析,纳入经醋酸阿比特龙联合泼尼松治疗后接受后续醋酸阿比特龙联合泼尼松(55例)或恩扎卢胺(33例)的转移性去势抵抗性前列腺癌患者。

主要发现

  • 后续醋酸阿比特龙联合泼尼松组PSA应答率(≥50% PSA下降,未确认)为44%,恩扎卢胺组为67%。
  • 后续醋酸阿比特龙联合泼尼松组中位至PSA进展时间为3.9个月(范围2.6-不可估计),恩扎卢胺组为2.8个月(范围1.8-不可估计)。
  • 多数患者(68%)在后续醋酸阿比特龙联合泼尼松或恩扎卢胺前接受了中间化疗。

临床怎么用

  • 作者认为,该分析不支持在初始醋酸阿比特龙联合泼尼松治疗后优先选择后续醋酸阿比特龙联合泼尼松或恩扎卢胺。

局限性

  • 原文指出事后分析存在局限性。
  • 原文指出两个治疗组均存在高删失率(>75%)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: In the COU-AA-302 trial, abiraterone acetate plus prednisone significantly increased overall survival for patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC). Limited information exists regarding response to subsequent androgen signaling-directed therapies following abiraterone acetate plus prednisone in patients with mCRPC. We investigated clinical outcomes associated with subsequent abiraterone acetate plus prednisone (55 patients) and enzalutamide (33 patients) in a post hoc analysis of COU-AA-302. Prostate-specific antigen (PSA) response was assessed. Median time to PSA progression was estimated using the Kaplan-Meier method. The PSA response rate (≥50% PSA decline, unconfirmed) was 44% and 67%, respectively. The median time to PSA progression was 3.9 mo (range 2.6-not estimable) for subsequent abiraterone acetate plus prednisone and 2.8 mo (range 1.8-not estimable) for subsequent enzalutamide. The majority of patients (68%) received intervening chemotherapy before subsequent abiraterone acetate plus prednisone or enzalutamide. While acknowledging the limitations of post hoc analyses and high censoring (>75%) in both treatment groups, these results suggest that subsequent therapy with abiraterone acetate plus prednisone or enzalutamide for patients who progressed on abiraterone acetate is associated with limited clinical benefit. PATIENT SUMMARY: This analysis showed limited clinical benefit for subsequent abiraterone acetate plus prednisone or enzalutamide in patients with metastatic castration-resistant prostate cancer following initial treatment with abiraterone acetate plus prednisone. This analysis does not support prioritization of subsequent abiraterone acetate plus prednisone or enzalutamide following initial therapy with abiraterone acetate plus prednisone.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Smith MR, Saad F, Rathkopf DE, et al. Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. 2017. PMID: 28314611. doi:10.1016/j.eururo.2017.03.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。